Key facts
- This page summarizes Luke Evnin's Form 4 filing for Werewolf Therapeutics, Inc. (HOWL).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 03 Jun 2026, 18:42.
Luke Evnin - 01 Jun 2026 Form 4 Insider Report for Werewolf Therapeutics, Inc. (HOWL)
- Reporting relationship
- Director
- Issuer ticker
- HOWL
- Reported as of
- 01 Jun 2026
- Net transaction value
- -$63,628
- SEC form
- 4
- Accepted by SEC
- 03 Jun 2026, 18:42:50 UTC
- Prior SEC filing
- 29 May 2026
- Next SEC filing
- 08 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Luke Evnin
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Luke Evnin filed Form 4 for Werewolf Therapeutics, Inc. (HOWL) on 03 Jun 2026.
Change
- Previous filing in this sequence was filed on 29 May 2026.
- Current net transaction value: -$63,628.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001134657
Primary reporting owner
EVNIN LUKE
- Relationship
- Director
- Address
- C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON
- Signature
- /s/ Luke Evnin
- Signature date
- 03 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HOWL
transaction
Common Stock
Sale
- Transaction value
- $37,816
- Shares
- -80,459
- Change %
- -13%
- Price
- $0.4700
- Shares after
- 542,120
- Date
- 01 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3, F4, F5
HOWL
transaction
Common Stock
Sale
- Transaction value
- $13,318
- Shares
- -29,595
- Change %
- -5.5%
- Price
- $0.4500
- Shares after
- 512,525
- Date
- 02 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F4, F6, F7, F8
HOWL
transaction
Common Stock
Sale
- Transaction value
- $12,495
- Shares
- -29,749
- Change %
- -5.8%
- Price
- $0.4200
- Shares after
- 482,776
- Date
- 03 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F4, F9, F10, F11
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 11 footnotes
Footnote F1
Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
Footnote F2
The shares were sold as follows: 8,620 by MPM Asset Management LLC ("AM LLC"), 54,428 by MPM BioVentures 2014, L.P. ("BV 2014"), 3,630 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 1,873 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 11,908 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.45 to $0.495 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Footnote F5
The shares are held as follows: 58,081 by AM LLC, 366,727 by BV 2014, 24,458 by BV 2014(B), 12,620 by AM BV2014 and 80,234 by MPM OIF.
Footnote F6
The shares were sold as follows: 3,171 by AM LLC, 20,020 by BV 2014, 1,335 by BV 2014(B), 689 by AM BV2014 and 4,380 by MPM OIF.
Footnote F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4304 to $0.46 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F8
The shares are held as follows: 54,910 by AM LLC, 346,707 by BV 2014, 23,123 by BV 2014(B), 11,931 by AM BV2014 and 75,854 by MPM OIF.
Footnote F9
The shares were sold as follows: 3,187 by AM LLC, 20,124 by BV 2014, 1,342 by BV 2014(B), 693 by AM BV2014 and 4,403 by MPM OIF.
Footnote F10
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.42 to $0.4367 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F11
The shares are held as follows: 51,723 by AM LLC, 326,583 by BV 2014, 21,781 by BV 2014(B), 11,238 by AM BV2014 and 71,451 by MPM OIF.